BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 29, 2023
Home » Topics » Antibody-drug conjugate, BioWorld

Antibody-drug conjugate, BioWorld
Antibody-drug conjugate, BioWorld RSS Feed RSS

Aimedbio researcher

Samsung fund buys equity in Korean ADC developer Aimedbio

Sep. 13, 2023
By Marian (YoonJee) Chu
No Comments
The Samsung Life Science Fund made its fourth equity investment into a South Korean antibody-drug conjugate (ADC) developer, Aimedbio Inc., to round out its investment portfolio padded with three other firms, including Jaguar Gene Therapy LLC, Senda Biosciences Inc. and Araris Biotech AG.
Read More

Genequantum strikes deal for its ADC conjugation technology with Inxmed

July 18, 2023
By Tamra Sami
No Comments
On the heels of a licensing deal last week, Genequantum Healthcare Co. Ltd. has struck another deal, this time out-licensing its conjugation technology to Inxmed Co. Ltd. to support development of next-generation targeted antibody-drug conjugates (ADCs).
Read More

Genequantum, Aimed partner again to develop five more ADCs

July 14, 2023
By Marian (YoonJee) Chu
No Comments
Another collaboration between two biopharmaceutical companies in the Asia-Pacific region is adding fuel to an already heated fire for antibody-drug conjugate (ADC) development worldwide. Suzhou, China-headquartered Genequantum Healthcare Co. Ltd. and South Korea’s Aimed Bio Inc. recently announced extending an existing partnership to jointly develop five ADC investigative drugs.
Read More

Building CDMO reach, Lotte Biologics partners with Kanaph for ADC-tech platform

July 11, 2023
By Marian (YoonJee) Chu
No Comments
Lotte Biologics Co. Ltd. said it partnered with domestic bioventure Kanaph Therapeutics Inc. to develop an antibody-drug conjugate (ADC) technology platform in hopes of rounding out a full, in-house ADC value-chain.
Read More

Kelun-Biotech raises $174M in Hong Kong IPO to race in ADC market

July 11, 2023
No Comments
Kelun-Biotech Biopharmaceutical Co. Ltd. raised HK$1.36 billion (US$174 million) in an IPO in Hong Kong to support its push into the increasingly competitive antibody-drug conjugate (ADC) market in China.
Read More

Beigene nabs option to preclinical ADC candidate in $1.3B Dualitybio deal

July 10, 2023
By Jennifer Boggs
No Comments
Extending its efforts in the booming antibody-drug conjugate (ADC) space, Beigene Co. Ltd. tapped Duality Biologics Co. Ltd. in a deal that could be worth a potential $1.3 billion, picking up an option for rights to a preclinical-stage ADC candidate targeting select solid tumors. It marks the seventh $1 billion-plus ADC-focused deal so far in 2023 and the second for Dualitybio, which inked a potential $1.7 billion deal in April.
Read More

BIO Korea 2023: Korean ecosystem offers advantages for clinical differentiation in hot areas like ADC

May 12, 2023
By Tamra Sami
No Comments
Korean biopharmas in the antibody-drug conjugate (ADC) space can leverage the strength of the Korean ecosystem when partnering with global pharma companies, said investors during the BIO Korea 2023 conference in Seoul on May 12.
Read More
Global handshake silhouette

In the ADC race, Eisai and Bliss enter one of the year’s biggest deals

May 8, 2023
By Lee Landenberger
No Comments
In the latest deal from the burgeoning antibody-drug conjugate (ADC) space, Eisai Co. Ltd. and privately held Bliss Biopharmaceutical (Hangzhou) Co. Ltd. reached a development and commercialization agreement that could be worth up to $2 billion. The massive collaboration is the eighth largest so far this year and one of three that involve ADCs in the year’s top 10 deals. The year’s biggest, according to BioWorld statistics, is the partnership extension between Evotec SE and Bristol Myers Squibb Co. to identify neurodegenerative disease therapies for eight years. The other ADC deals involve Synaffix BV, which signed a $2 billion pact in January with Amgen Inc., and a $2.2 billion expanded deal in February with Macrogenics Inc.
Read More
Concept of business partnership

Legochem out-licenses ADC targets to Amgen in ₩1.6 trillion deal

Dec. 27, 2022
By Tamra Sami
No Comments
South Korea’s Legochem Bioscience Inc. inked a licensing deal with Amgen Inc. on Dec. 23 for five undisclosed antibody drug conjugate (ADC) targets worth up to ₩1.6 trillion (US$1.24 billion). Under the terms of the deal, Legochem will out-license global rights to Amgen for five undisclosed ADC targets and will receive an undisclosed up-front payment as well as development milestones and sales royalties. The companies did not disclose additional details.
Read More
Antibody-drug conjugate illustration

The year’s biggest deal: Merck and Kelun enter $9.3B alliance

Dec. 22, 2022
By Lee Landenberger
No Comments
Two deals for antibody-drug conjugates inked since May between Merck & Co. Inc. and Sichuan Kelun-Biotech Pharmaceutical Co. Ltd. have blossomed eight months later into the year’s biggest agreement, one that could bring Kelun-Biotech up to $9.3 billion in development, regulatory and sales milestones.
Read More
Previous 1 2 3 4 5 6 7 8 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 28, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 28, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing